Strekin AG Secures CHF 10 Million Financing for Further Development of STR001 in Sudden Hearing Loss

Strekin’s development candidate, STR001, obtains EU orphan drug designation for the treatment
of Sudden Sensorineural Hearing Loss

Strekin AG Presents Update on Phase 2 Development of STR001 and New Preclinical Data in Hearing Loss

Strekin AG announces the presentation of key STR001 data at the Conference on Molecular Biology of Hearing and Deafness, Cambridge UK

Strekin AG to develop the P38 MAPK inhibitor Pamapimod

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued.